FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017030602> ?p ?o ?g. }

• W2017030602 endingPage "998" @default.
• W2017030602 startingPage "991" @default.
• W2017030602 abstract "BACKGROUND Promising results from a Phase II trial of induction chemotherapy and sequential radiotherapy for advanced nasopharyngeal carcinoma (NPC) at The University of Texas M. D. Anderson Cancer Center (Houston, TX) and two retrospective reviews of the authors' historical experience with NPC demonstrated that distant failure was directly correlated with advanced lymph node status. Furthermore, local control was excellent for patients with T1–3 disease that was managed with radiation alone or with a sequential approach involving chemotherapy. Neoadjuvant chemotherapy (primarily with cisplatin + 5-fluorouracil) was associated with a significantly decreased risk of distant metastasis and with improved survival. Based on these findings, the authors evaluated a novel induction regimen involving docetaxel and carboplatin for patients with previously untreated T1–2N2–3M0 NPC. METHODS Docetaxel (80 mg/m2 on Day 1) and carboplatin (to an area under the time-concentration curve of 6 on Day 1) were administered every 21 days for 3 cycles, after which radiotherapy was administered. NPC was restaged with magnetic resonance imaging and nasopharyngoscopy 3 weeks after the completion of chemotherapy and 6 weeks after the completion of radiotherapy. RESULTS Over 5 years, 18 patients were enrolled in the study. Grade 4 neutropenia and Grade 2 fatigue were observed in 51% and 28% of chemotherapy courses, respectively. After chemotherapy, 2 patients had complete responses, 14 had partial responses, 1 had a minor response, and 1 had progressive disease. The latter two patients and one patient who had a partial response underwent off-study chemoradiotherapy. After radiotherapy or chemoradiotherapy, 12 patients had complete responses and 6 had partial responses. Seven patients had recurrent disease; two had local recurrences, and five had distant metastases. CONCLUSIONS Although unlikely to be superior to cisplatin + 5-fluorouracil, the trial regimen could be administered quickly in the outpatient setting, was logistically more convenient for the patient, and was devoid of serious nonhematologic toxic effects. We believe that the risk-based approach examined in the current study merits further investigation. Cancer 2004;100:991–8. © 2004 American Cancer Society." @default.
• W2017030602 created "2016-06-24" @default.
• W2017030602 creator A5002490436 @default.
• W2017030602 creator A5005803971 @default.
• W2017030602 creator A5008790176 @default.
• W2017030602 creator A5017187936 @default.
• W2017030602 creator A5019885624 @default.
• W2017030602 creator A5024203346 @default.
• W2017030602 creator A5044925532 @default.
• W2017030602 creator A5052697285 @default.
• W2017030602 creator A5059710197 @default.
• W2017030602 creator A5061124523 @default.
• W2017030602 creator A5073466449 @default.
• W2017030602 date "2004-01-01" @default.
• W2017030602 modified "2023-10-11" @default.
• W2017030602 title "A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status" @default.
• W2017030602 cites W1510484686 @default.
• W2017030602 cites W1550111394 @default.
• W2017030602 cites W1585834668 @default.
• W2017030602 cites W1765857451 @default.
• W2017030602 cites W1902822116 @default.
• W2017030602 cites W1916546429 @default.
• W2017030602 cites W1974159372 @default.
• W2017030602 cites W1984396523 @default.
• W2017030602 cites W2011587308 @default.
• W2017030602 cites W2015167754 @default.
• W2017030602 cites W2016276011 @default.
• W2017030602 cites W2035377014 @default.
• W2017030602 cites W2045943543 @default.
• W2017030602 cites W2051146188 @default.
• W2017030602 cites W2051367322 @default.
• W2017030602 cites W2075214861 @default.
• W2017030602 cites W2084803897 @default.
• W2017030602 cites W2111140446 @default.
• W2017030602 cites W2116996913 @default.
• W2017030602 cites W2125919881 @default.
• W2017030602 cites W2146749028 @default.
• W2017030602 cites W2165063184 @default.
• W2017030602 cites W2184400718 @default.
• W2017030602 cites W2185154108 @default.
• W2017030602 cites W2256976018 @default.
• W2017030602 cites W2262506539 @default.
• W2017030602 cites W81042631 @default.
• W2017030602 doi "https://doi.org/10.1002/cncr.20079" @default.
• W2017030602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14983495" @default.
• W2017030602 hasPublicationYear "2004" @default.
• W2017030602 type Work @default.
• W2017030602 sameAs 2017030602 @default.
• W2017030602 citedByCount "34" @default.
• W2017030602 countsByYear W20170306022012 @default.
• W2017030602 countsByYear W20170306022013 @default.
• W2017030602 countsByYear W20170306022016 @default.
• W2017030602 countsByYear W20170306022017 @default.
• W2017030602 countsByYear W20170306022021 @default.
• W2017030602 crossrefType "journal-article" @default.
• W2017030602 hasAuthorship W2017030602A5002490436 @default.
• W2017030602 hasAuthorship W2017030602A5005803971 @default.
• W2017030602 hasAuthorship W2017030602A5008790176 @default.
• W2017030602 hasAuthorship W2017030602A5017187936 @default.
• W2017030602 hasAuthorship W2017030602A5019885624 @default.
• W2017030602 hasAuthorship W2017030602A5024203346 @default.
• W2017030602 hasAuthorship W2017030602A5044925532 @default.
• W2017030602 hasAuthorship W2017030602A5052697285 @default.
• W2017030602 hasAuthorship W2017030602A5059710197 @default.
• W2017030602 hasAuthorship W2017030602A5061124523 @default.
• W2017030602 hasAuthorship W2017030602A5073466449 @default.
• W2017030602 hasBestOaLocation W20170306021 @default.
• W2017030602 hasConcept C126322002 @default.
• W2017030602 hasConcept C141071460 @default.
• W2017030602 hasConcept C143998085 @default.
• W2017030602 hasConcept C2776611710 @default.
• W2017030602 hasConcept C2776694085 @default.
• W2017030602 hasConcept C2777063308 @default.
• W2017030602 hasConcept C2778239845 @default.
• W2017030602 hasConcept C2778424827 @default.
• W2017030602 hasConcept C2778850193 @default.
• W2017030602 hasConcept C2778997737 @default.
• W2017030602 hasConcept C2781190966 @default.
• W2017030602 hasConcept C2781413609 @default.
• W2017030602 hasConcept C2781451048 @default.
• W2017030602 hasConcept C509974204 @default.
• W2017030602 hasConcept C71924100 @default.
• W2017030602 hasConceptScore W2017030602C126322002 @default.
• W2017030602 hasConceptScore W2017030602C141071460 @default.
• W2017030602 hasConceptScore W2017030602C143998085 @default.
• W2017030602 hasConceptScore W2017030602C2776611710 @default.
• W2017030602 hasConceptScore W2017030602C2776694085 @default.
• W2017030602 hasConceptScore W2017030602C2777063308 @default.
• W2017030602 hasConceptScore W2017030602C2778239845 @default.
• W2017030602 hasConceptScore W2017030602C2778424827 @default.
• W2017030602 hasConceptScore W2017030602C2778850193 @default.
• W2017030602 hasConceptScore W2017030602C2778997737 @default.
• W2017030602 hasConceptScore W2017030602C2781190966 @default.
• W2017030602 hasConceptScore W2017030602C2781413609 @default.
• W2017030602 hasConceptScore W2017030602C2781451048 @default.
• W2017030602 hasConceptScore W2017030602C509974204 @default.
• W2017030602 hasConceptScore W2017030602C71924100 @default.
• W2017030602 hasIssue "5" @default.

• next